All Pharma News
price-trendAsk Us
Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022

Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022
GLOBENEWSWIRE
03 Feb 2023
Share Share
Regulatory filing for house dust mite allergy tablet accepted for review

Regulatory filing for house dust mite allergy tablet accepted for review
GLOBENEWSWIRE
03 Feb 2023
Share Share
ALK – Financial calendar for the 2023 financial year

ALK – Financial calendar for the 2023 financial year
GLOBENEWSWIRE
19 Dec 2022
Share Share
ALK spotlights the impact of respiratory allergies on children at EAACI Congress

ALK spotlights the impact of respiratory allergies on children at EAACI Congress
GLOBENEWSWIRE
03 Jul 2022
Share Share
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy

ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
GLOBENEWSWIRE
27 Jun 2022
Share Share
Azenta to Participate in the UBS Global Healthcare Conference

Azenta to Participate in the UBS Global Healthcare Conference
PRNEWSWIRE
19 May 2022
Share Share
Clinical trial waiver in China opens door to 2022 registration filing

Clinical trial waiver in China opens door to 2022 registration filing
GLOBENEWSWIRE
03 Mar 2022
Share Share
Merck shocks ALK by returning rights to allergy immunotherapies

Merck shocks ALK by returning rights to allergy immunotherapies
Nick Paul Taylor FIERCE BIOTECH
28 Jul 2016
Share Share
US FDA finds cGMP deviations at ALK-Abello facility in Denmark

US FDA finds cGMP deviations at ALK-Abello facility in Denmark
IN PHARMATECHNOLOGIST
26 Jul 2016
Share Share